Abstract
Aim: Toevaluate thepotential of IGF1R as a prognostic marker for high-grade serous ovarian cancer (HGSOC) patients.Patients & methods: The expression levels of IGF1R and drug transporters (ABCB1, hCtr1) were measured longitudinally in chemo-naive and chemo-treated tumor samples from 19 HGSOC patients, and their correlation with the clinical outcome was examined. Results:IGF1R expression was significantly upregulated in treated tumor samples, which positively correlated with hCtr1 levels. Patients with metastatic tumors with IGF1R expression higher than median showed better overall survival (median not reached) and disease-free survival (26.7months) than those with less than median expression (overall survival: 27.5months [p=0.029]; disease-free survival: 11.9months [p=0.014]). Conclusion: IGF1R prognosticates prolonged survival in HGSOC patients, possibly due to its positive correlation with hCtr1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
